Chronic Hepatitis B Market Anticipating Remarkable Growth by 2032, Insights by DelveInsight | Dicerna, GlaxoSmithKline, Ionis, Gilead, Roche, Janssen, Replicor, Arbutus Biopharma, Assembly Biosciences

Chronic Hepatitis B Market Anticipating Remarkable Growth by 2032, Insights by DelveInsight | Dicerna, GlaxoSmithKline, Ionis, Gilead, Roche, Janssen, Replicor, Arbutus Biopharma, Assembly Biosciences
Delveinsight Business Research LLP
The Chronic Hepatitis B Market size in the 7MM was USD 1,500 million in 2022 and it is projected to increase during the forecast period (2023–2032). As per DelveInsight, the Chronic Hepatitis B Market is anticipated to evolve immensely in the coming years owing to the increase in prevalence, increased R&D for developing new molecules, advancement in vaccine technology, expected commercial success of upcoming therapies, along with a hike in the usage of approved therapies in the 7MM.

DelveInsight’s “Chronic Hepatitis B Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Hepatitis B market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Chronic Hepatitis B drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Chronic Hepatitis B treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Chronic Hepatitis B: An Overview

Hepatitis B is a potentially life-threatening and one of the most common liver infections caused by the hepatitis B virus (HBV), which attacks and injures the liver. A hepatitis B infection can result in either an acute or chronic infection. If an individual suffers from an HBV infection that lasts more than 6 months, the infection becomes chronic. Chronic hepatitis B (CHB) increases the risk of developing liver failure, liver cancer, or cirrhosis. The risk of developing a CHB infection is also directly related to the age at which one first becomes exposed to the hepatitis B virus.

Hepatitis B is a “silent epidemic” because most people do not exhibit symptoms when they are newly infected or chronically infected. As a result, they have the potential to unintentionally infect others and prolong the slow spread of hepatitis B.

CHB infection is treated with either interferon or oral antiviral agents. These treatments are expected to slow the progression of cirrhosis, reduce the incidence of liver cancer, and improve long-term survival. Among antiviral agents, entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide (TAF) are recommended as the first choice of treatment regimens. Liver transplantation may be considered in cases of chronic liver failure.

The hepatitis B vaccine is given as a series of three or four injections administered over 6 months. The first dose of the vaccine is sometimes called the birth dose since it is frequently given within the first 24 hours of birth. The vaccine is 90–95% effective in preventing hepatitis B. Additionally, the WHO advises using prophylaxis and immunization to stop the mother-to-child transmission of hepatitis B.

Chronic Hepatitis B Market Key Facts

  • The Chronic Hepatitis B Market in the 7MM will increase at a CAGR of 24% due to increasing awareness of the disease and WHO initiatives and the launch of the emerging therapy aiming at a functional cure.

  • Among EU4, Germany accounts for the maximum market size in 2022, while Spain occupies the bottom of the ladder in 2022.

  • According to the World Health Organization (WHO) estimates, in 2015, 257 million people were living with chronic hepatitis B infection. Also, as of 2016, 27 million people (10.5% of all people estimated to be living with hepatitis B) were aware of their infection, while 4.5 million (16.7%) of the people diagnosed were on treatment. 

  • According to the latest WHO estimates, the proportion of children under 5 years of age chronically infected with HBV dropped to just under 1% in 2019, down from around 5% in the pre-vaccine era ranging from the 1980s to the early 2000s.

  • The total prevalent cases of Chronic Hepatitis B in the 7MM comprised approximately 56,333,000+ cases in 2022.

  • The total prevalent cases of Chronic Hepatitis B in the United States were around 22,56,000+ cases in 2022.

  • In the United States, approximately 55% of the patient share is attributed to males, whereas around 40% of females suffer from Chronic Hepatitis B.

  • Among the EU4, Germany accounted for the largest number of Chronic Hepatitis B cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.

Chronic Hepatitis B Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Chronic Hepatitis B pipeline therapies. It also thoroughly assesses the Chronic Hepatitis B market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Chronic Hepatitis B drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Chronic Hepatitis B Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Chronic Hepatitis B epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Chronic Hepatitis B epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Chronic Hepatitis B Epidemiology, Segmented as –

  • Prevalent Cases of CHB in the 7MM (2019–2032)

  • Diagnosed Prevalent Cases of CHB in the 7MM (2019–2032)

  • Age-specific Diagnosed Prevalent Cases of CHB in the 7MM (2019–2032)

  • Gender-specific Diagnosed Prevalent Cases of CHB in the 7MM (2019–2032)

  • Type-specific Diagnosed Prevalent Cases of CHB in the 7MM (2019–2032)

  • Total Treated Cases of CHB in the 7MM (2019–2032)

Chronic Hepatitis B Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Chronic Hepatitis B market or expected to be launched during the study period. The analysis covers the Chronic Hepatitis B market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Chronic Hepatitis B drugs based on their sale and market share.

The report also covers the Chronic Hepatitis B pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Chronic Hepatitis B companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Chronic Hepatitis B Market Will Evolve and Grow by 2032 @

Chronic Hepatitis B Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Chronic Hepatitis B Virus Infection. Currently, Ligand Pharmaceuticals is leading the therapeutics market with its Chronic Hepatitis B Virus Infection drug candidates in the most advanced stage of clinical development.

Chronic Hepatitis B Companies Actively Working in the Therapeutics Market Include

Antios Therapeutics, Arbutus Biopharma, Ascentage Pharma, Ascletis Pharmaceuticals, Assembly Biosciences, Brii Biosciences, Chong Kun Dang Pharmaceutical, Dong-A ST Co, Enanta Pharmaceuticals, Enyo Pharma, Gilead Sciences, GlaxoSmithKline, Golden Biotechnology, Guangzhou Lupeng Pharmaceutical, Henlix, Janssen Sciences, Jiangsu HengRui Medicine, Nucorion Pharmaceuticals, PharmaEssentia, Qilu Pharmaceutical, Romark Laboratories, Shanghai HEP Pharmaceutical, Sunshine Lake Pharma, Suzhou Ribo Life Science, Tasly Tianjin Biopharmaceutical, Vaccitech limited, Vaxine Pty Ltd, Vedanta Biosciences, VenatoRx Pharmaceuticals, Vir Biotechnology, Zhejiang Palo Alto Pharmaceuticals, Zhimeng Biopharm, and others. 

Emerging and Marketed Chronic Hepatitis B Therapies Covered in the Report Include:

  • Pradefovir: Ligand Pharmaceuticals

  • RG6346: Dicerna Pharmaceuticals

  • GSK3228836 (IONIS-HBVRx): GlaxoSmithKline/Ionis Pharma

  • Selgantolimod (GS-9688): Gilead Sciences

  • RG7854/RG7907/RG6346: Roche

  • JNJ-73763989 and/or JNJ-56136379: Janssen/Arrowhead Pharmaceuticals

  • GSK3389404 (IONIS-HBV-LRX): GlaxoSmithKline /Ionis Pharmaceuticals

  • Vebicorvir (VBR, or ABI-H0731): Assembly Biosciences

  • VIR-2218 + VIR-3434: Vir Biotechnology

  • REP 2165 + REP 2139: Replicor

  • AB-729 (GaINAc-RNAi): Arbutus Biopharma

And Many More

The Report Covers an In-depth Assessment of Emerging Drugs and key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Chronic Hepatitis B Competitive Intelligence Analysis

4. Chronic Hepatitis B Market Overview at a Glance

5. Chronic Hepatitis B Disease Background and Overview

6. Chronic Hepatitis B Patient Journey

7. Chronic Hepatitis B Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Chronic Hepatitis B Treatment Algorithm, Current Treatment, and Medical Practices

9. Chronic Hepatitis B Unmet Needs

10. Key Endpoints of Chronic Hepatitis B Treatment

11. Chronic Hepatitis B Marketed Therapies

12. Chronic Hepatitis B Emerging Drugs and Latest Therapeutic Advances

13. Chronic Hepatitis B Seven Major Market Analysis

14. Attribute Analysis

15. Chronic Hepatitis B Market Outlook (In US, EU5, and Japan)

16. Chronic Hepatitis B Companies Active in the Market

17. Chronic Hepatitis B Access and Reimbursement Overview

18. KOL Views on the Chronic Hepatitis B Market

19. Chronic Hepatitis B Market Drivers

20. Chronic Hepatitis B Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Point of Care Glucose Testing Market

“Point of Care Glucose Testing Market Insight, Competitive Landscape, and Market Forecast, 2028” report delivers an in-depth understanding of historical and forecasted Point of Care Glucose Testing market size, share, and trends globally, which comprises North America, Europe, APAC, and RoW. The report provides insight into the clinical, commercial & regulatory development in the Point of Care Glucose Testing Market. Furthermore, it also covers emerging products and key companies actively operating in the market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States